Posts by Mourabit Halima

At the recently concluded American Society of Hematology (ASH) Annual Meeting in 2025, Dr. Hanny Al-Samkari from Massachusetts General Hospital presented the highly anticipated primary analysis of the VAYHIT 2 study. Presented as a Late-Breaking Abstract (LBA), this global, randomized, double-blind, Phase 3 clinical trial evaluated the efficacy and safety of combining the novel BAFF receptor antagonist Ianalumab with Eltrombopag in patients with primary immune thrombocytopenia (ITP). The results signal a potential paradigm shift for patients who have failed first-line corticosteroid therapy, offering a new avenue for durable disease control.

At the Late-Breaking Abstract (LBA) session of the 2025 American Society of Hematology (ASH) Annual Meeting, Dr. María-Victoria Mateos, representing the research team, unveiled the highly anticipated results of the MAJEStec-3 study. This marks the first reported Phase III clinical trial of a BCMA-targeted bispecific antibody. Comparing the combination of Teclistamab and Daratumumab ("Tech-Dara") against standard-of-care regimens (Dara-Pd or Dara-Vd) in patients with relapsed/refractory multiple myeloma (RRMM), the study delivered historic results. The Tech-Dara combination achieved a Hazard Ratio (HR) for progression-free survival of 0.17—the most profound efficacy signal reported to date for BCMA-targeted therapies—signaling a potential "functional cure" for patients with early relapse.

At the 67th American Society of Hematology (ASH) Annual Meeting in 2025, a groundbreaking Late-Breaking Abstract (LBA) presented by Professor Phoebe Joy Ho (Royal Prince Alfred Hospital, Australia) signaled a potential paradigm shift in the treatment of multiple myeloma. The preliminary results from the Phase 1 inMMyCAR study of KLN-1010—the first in vivo anti-BCMA CAR-T therapy—demonstrated that deep molecular responses can be achieved without the complex logistics of ex vivo manufacturing or the toxicities associated with lymphodepleting chemotherapy.

In this video, Prof. Hanny Al-Samkari of Harvard Medical School shares key insights from the VEHIT-2 Phase III randomized trial evaluating ianalumab in early second-line immune thrombocytopenia (ITP). He discusses…

Lymphoma diagnosis and treatment are entering a phase of accelerated evolution, with breakthrough therapies and innovative research continuously reshaping clinical practice. From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was grandly held in Orlando. At this year’s congress, multidimensional and in-depth innovations emerged across both aggressive lymphoma precision therapy and long-term disease management for indolent lymphomas.

At ASH 2025, Prof. Jeff Sharman from the Willamette Valley Cancer Research Institute shares key clinical insights on mosunetuzumab, focusing on its safety, efficacy, and durability of response, particularly in…

At ASH 2025, Dr. Shannuo Li from the University of Utah, USA shares her perspective on emerging strategies for multi-target immune engagement, exploring the potential of simultaneously targeting BCMA, CD38,…

At the recent Annual Meeting of the American Society of Hematology (ASH), the team led by Professor Cai Zhen and Professor He Jingsong from The First Affiliated Hospital, Zhejiang University School of Medicine, had 12 studies accepted, comprehensively showcasing systematic investigations in multiple myeloma ranging from basic research to clinical translation. These studies focused on key scientific questions including the roots of disease relapse, mechanisms of drug resistance, prognostic evaluation, and therapeutic strategies, forming an integrated evidence chain from mechanistic discovery to clinical application. During the meeting, Hematology Frontier invited Professor Cai Zhen to provide an in-depth interpretation of the team’s research achievements and outline future research plans, offering valuable academic insights to advance the diagnosis and treatment of multiple myeloma.

The 67th Annual Meeting of the American Society of Hematology (ASH) was held from December 6 to 9, 2025, in Orlando, bringing together the latest global advances in hematology research and clinical practice. At this year’s meeting, the team led by Professor Hu Kai from Beijing Gaobo Hospital presented seven studies focusing on CAR-T cell therapy across different types of relapsed/refractory lymphoma, including B-cell lymphoma, central nervous system lymphoma, T-cell lymphoma, as well as combined strategies involving CAR-T therapy and hematopoietic stem cell transplantation. These studies provide important evidence supporting the further development of individualized treatment strategies. Oncology Frontier – Hematology Frontier invited Professor Hu Kai to provide an in-depth interpretation of these key findings and their clinical significance.